Cancer name Lung Cancer
Cancer Type LUCA
Immunotherapy type Oncolytic viruses
Treatment VSVΔ51-IFNγ
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature TNF-α
Official Symbol TNF
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description To test this, we isolated serum from treated animals and IFNγ, interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and mono-cyte chemoattractant protein-1 (MCP-1) concentrations were determined using cytometric bead arrays. All the factors tested were higher in both virus-treated groups compared with PBS-treated animals, consistent with an immune response to viral infection.
PMID 27119116
Title Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity